Johnson & Johnson Research and Development in Process
Johnson & Johnson (JNJ) reported Research and Development in Process of $49.00 million for the 3-month period ending 2023-04-02, per its 10-Q filed 2023-04-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-04-28
- Johnson & Johnson research and development in process for the quarter ending 2023-04-02 was $49.00M, a 91.97% decline year-over-year.
- Johnson & Johnson research and development in process for the quarter ending 2023-01-01 was $173.00M.
- Johnson & Johnson research and development in process for the quarter ending 2022-10-02 was $0.00, a 100.00% decline year-over-year.
- Johnson & Johnson research and development in process for the quarter ending 2022-07-03 was $0.00.
- Johnson & Johnson research and development in process for fiscal 2023 was $783.00M, a 13.00% decline from fiscal 2022.
- Johnson & Johnson research and development in process for fiscal 2022 was $900.00M, a 397.24% increase from fiscal 2021.
- Johnson & Johnson research and development in process for fiscal 2021 was $181.00M, a 79.66% decline from fiscal 2019.
- Johnson & Johnson research and development in process for fiscal 2019 was $890.00M, a 20.96% decline from fiscal 2018.
| Period end | Research and Development in Process 3 month | Research and Development in Process 3 month as first filed | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|---|
| 2023-04-02 | $49.00M 10-Q · filed 2023-04-28 | $222.00M derived: sum of 2 quarters · filed 2023-04-28 | $222.00M derived: sum of 3 quarters · filed 2023-04-28 | $222.00M derived: sum of 4 quarters · filed 2023-04-28 | |
| 2023-01-01 | $173.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $173.00M derived: sum of 2 quarters · filed 2023-02-16 | $173.00M derived: sum of 3 quarters · filed 2023-02-16 | $783.00M 10-K · filed 2023-02-16 | |
| 2022-10-02 | $0.00 10-Q · filed 2022-10-27 | $0.00 derived: sum of 2 quarters · filed 2022-10-27 | $610.00M 10-Q · filed 2022-10-27 | $610.00M derived: sum of 4 quarters · filed 2023-04-28 | |
| 2022-07-03 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $610.00M 10-Q · filed 2022-07-29 | $610.00M derived: sum of 3 quarters · filed 2023-04-28 | $1.51B derived: sum of 4 quarters · filed 2023-04-28 | |
| 2022-04-03 | $610.00M 10-Q · filed 2023-04-28 | $610.00M derived: sum of 2 quarters · filed 2023-04-28 | $1.51B derived: sum of 3 quarters · filed 2023-04-28 | $1.51B derived: sum of 4 quarters · filed 2023-04-28 | |
| 2022-01-02 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $900.00M derived: sum of 2 quarters · filed 2023-02-16 | $900.00M derived: sum of 3 quarters · filed 2023-02-16 | $900.00M 10-K · filed 2023-02-16 | |
| 2021-10-03 | $900.00M 10-Q · filed 2022-10-27 | $900.00M derived: sum of 2 quarters · filed 2022-10-27 | $900.00M 10-Q · filed 2022-10-27 | $937.00M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-07-04 | $0.00 10-Q · filed 2021-07-29 | $0.00 10-Q · filed 2022-07-29 | $37.00M derived: sum of 3 quarters · filed 2023-02-16 | $175.00M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-04-04 | $0.00 10-Q · filed 2022-04-29 | $37.00M derived: sum of 2 quarters · filed 2023-02-16 | $175.00M derived: sum of 3 quarters · filed 2023-02-16 | $181.00M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-01-03 | $37.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $175.00M derived: sum of 2 quarters · filed 2023-02-16 | $181.00M derived: sum of 3 quarters · filed 2023-02-16 | $181.00M 10-K · filed 2023-02-16 | |
| 2020-09-27 | $138.00M 10-Q · filed 2021-10-29 | $144.00M derived: sum of 2 quarters · filed 2021-10-29 | $144.00M 10-Q · filed 2021-10-29 | $144.00M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2020-06-28 | $6.00M 10-Q · filed 2021-07-29 | $6.00M 10-Q · filed 2021-07-29 | $6.00M derived: sum of 3 quarters · filed 2022-02-17 | $6.00M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2020-03-29 | $0.00 10-Q · filed 2020-04-29 | $0.00 derived: sum of 2 quarters · filed 2022-02-17 | $0.00 derived: sum of 3 quarters · filed 2022-02-17 | $0.00 derived: sum of 4 quarters · filed 2022-02-17 | |
| 2019-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $0.00 derived: sum of 2 quarters · filed 2022-02-17 | $0.00 derived: sum of 3 quarters · filed 2022-02-17 | $890.00M 10-K · filed 2022-02-17 | |
| 2019-09-29 | $0.00 10-Q · filed 2020-10-23 | $0.00 derived: sum of 2 quarters · filed 2020-10-23 | $890.00M 10-Q · filed 2020-10-23 | $890.00M derived: sum of 4 quarters · filed 2021-02-22 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-07-24 | $890.00M 10-Q · filed 2020-07-24 | $890.00M derived: sum of 3 quarters · filed 2021-02-22 | $2.02B derived: sum of 4 quarters · filed 2021-02-22 | |
| 2019-03-31 | $890.00M 10-Q · filed 2020-04-29 | $890.00M derived: sum of 2 quarters · filed 2021-02-22 | $2.02B derived: sum of 3 quarters · filed 2021-02-22 | $2.02B derived: sum of 4 quarters · filed 2021-02-22 | |
| 2018-12-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-22 | $1.13B derived: sum of 2 quarters · filed 2021-02-22 | $1.13B derived: sum of 3 quarters · filed 2021-02-22 | $1.13B 10-K · filed 2021-02-22 | |
| 2018-09-30 | $1.13B 10-K · filed 2020-02-18 | $1.13B derived: sum of 2 quarters · filed 2020-02-18 | $1.13B 10-Q · filed 2019-10-28 | $1.53B derived: sum of 4 quarters · filed 2020-02-18 | |
| 2018-07-01 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $0.00 10-Q · filed 2019-07-29 | $408.00M derived: sum of 3 quarters · filed 2019-07-29 | $408.00M derived: sum of 4 quarters · filed 2019-07-29 | |
| 2018-04-01 | $0.00 10-Q · filed 2019-05-01 | $408.00M derived: sum of 2 quarters · filed 2019-05-01 | $408.00M derived: sum of 3 quarters · filed 2019-05-01 | $408.00M derived: sum of 4 quarters · filed 2019-05-01 | |
| 2017-12-31 | $408.00M 10-K · filed 2019-02-20 | $408.00M derived: sum of 2 quarters · filed 2019-02-20 | $408.00M derived: sum of 3 quarters · filed 2019-02-20 | $408.00M 10-K · filed 2020-02-18 | |
| 2017-10-01 | $0.00 10-Q · filed 2018-10-31 | $0.00 derived: sum of 2 quarters · filed 2018-10-31 | $0.00 10-Q · filed 2018-10-31 | ||
| 2017-07-02 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | |||
| 2017-01-01 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $0.00 derived: sum of 2 quarters · filed 2019-02-20 | $29.00M derived: sum of 3 quarters · filed 2019-02-20 | $29.00M 10-K · filed 2019-02-20 | |
| 2016-10-02 | $0.00 10-Q · filed 2016-11-04 | $29.00M derived: sum of 2 quarters · filed 2017-08-03 | $29.00M 10-Q · filed 2017-11-02 | ||
| 2016-07-03 | $29.00M 10-Q · filed 2017-08-03 | $29.00M 10-Q · filed 2017-08-03 | |||
| 2016-01-03 | $214.00M 10-K · filed 2017-02-27 | $224.00M derived: sum of 2 quarters · filed 2017-02-27 | $224.00M derived: sum of 3 quarters · filed 2017-02-27 | $224.00M 10-K · filed 2018-02-21 | |
| 2015-09-27 | $10.00M 10-Q · filed 2016-11-04 | $10.00M derived: sum of 2 quarters · filed 2016-11-04 | $10.00M 10-Q · filed 2016-11-04 | $166.00M derived: sum of 4 quarters · filed 2016-11-04 | |
| 2015-06-28 | $0.00 10-Q · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | $156.00M derived: sum of 3 quarters · filed 2016-08-04 | $156.00M derived: sum of 4 quarters · filed 2016-08-04 | |
| 2015-03-29 | $0.00 10-Q · filed 2015-05-01 | $156.00M derived: sum of 2 quarters · filed 2016-02-24 | $156.00M derived: sum of 3 quarters · filed 2016-02-24 | $160.00M derived: sum of 4 quarters · filed 2016-02-24 | |
| 2014-12-28 | $156.00M 10-K · filed 2016-02-24 | $156.00M derived: sum of 2 quarters · filed 2016-02-24 | $160.00M derived: sum of 3 quarters · filed 2016-02-24 | $178.00M 10-K · filed 2017-02-27 | |
| 2014-09-28 | $0.00 10-Q · filed 2015-10-30 | $4.00M derived: sum of 2 quarters · filed 2015-10-30 | $22.00M 10-Q · filed 2015-10-30 | $360.00M derived: sum of 4 quarters · filed 2015-10-30 | |
| 2014-06-29 | $4.00M 10-Q · filed 2015-07-31 | $22.00M 10-Q · filed 2015-07-31 | $360.00M derived: sum of 3 quarters · filed 2015-07-31 | $538.00M derived: sum of 4 quarters · filed 2015-07-31 | |
| 2014-03-30 | $18.00M 10-Q · filed 2015-05-01 | $356.00M derived: sum of 2 quarters · filed 2015-05-01 | $534.00M derived: sum of 3 quarters · filed 2015-05-01 | $534.00M derived: sum of 4 quarters · filed 2015-05-01 | |
| 2013-12-29 | $338.00M 10-K · filed 2015-02-24 | $294.00M 10-K · filed 2014-02-21 | $516.00M derived: sum of 2 quarters · filed 2015-02-24 | $516.00M derived: sum of 3 quarters · filed 2015-02-24 | $580.00M 10-K · filed 2016-02-24 |
| 2013-09-29 | $178.00M 10-K · filed 2015-02-24 | $178.00M derived: sum of 2 quarters · filed 2015-02-24 | $242.00M 10-Q · filed 2014-10-30 | $301.00M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-01 | $64.00M 10-Q · filed 2014-08-01 | $123.00M derived: sum of 3 quarters · filed 2014-08-01 | $463.00M derived: sum of 4 quarters · filed 2014-08-01 | |
| 2013-03-31 | $64.00M 10-Q · filed 2014-05-02 | $123.00M derived: sum of 2 quarters · filed 2014-05-02 | $463.00M derived: sum of 3 quarters · filed 2014-05-02 | $807.00M derived: sum of 4 quarters · filed 2014-05-02 | |
| 2012-12-30 | $59.00M 10-K · filed 2014-02-21 | $399.00M derived: sum of 2 quarters · filed 2014-02-21 | $743.00M derived: sum of 3 quarters · filed 2014-02-21 | $1.16B 10-K · filed 2015-02-24 | |
| 2012-09-30 | $340.00M 10-K · filed 2014-02-21 | $679.00M 10-Q · filed 2012-11-09 | $684.00M derived: sum of 2 quarters · filed 2014-02-21 | $1.11B 10-Q · filed 2013-11-04 | $684.00M derived: sum of 4 quarters · filed 2014-02-21 |
| 2012-07-01 | $344.00M 10-K · filed 2014-02-21 | $429.00M 10-Q · filed 2012-08-02 | $429.00M 10-Q · filed 2013-08-01 | $344.00M derived: sum of 3 quarters · filed 2014-02-21 | $344.00M derived: sum of 4 quarters · filed 2014-02-21 |
| 2012-04-01 | $0.00 10-Q · filed 2013-05-03 | $0.00 derived: sum of 2 quarters · filed 2014-02-21 | $0.00 derived: sum of 3 quarters · filed 2014-02-21 | $0.00 derived: sum of 4 quarters · filed 2014-02-21 | |
| 2012-01-01 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $0.00 derived: sum of 2 quarters · filed 2014-02-21 | $0.00 derived: sum of 3 quarters · filed 2014-02-21 | $0.00 10-K · filed 2014-02-21 | |
| 2011-10-02 | $0.00 10-Q · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | $0.00 10-Q · filed 2012-11-09 | ||
| 2011-07-03 | $0.00 10-Q · filed 2012-08-02 | $0.00 10-Q · filed 2012-08-02 | |||
| 2011-01-02 | $0.00 10-K · filed 2013-02-22 | ||||
| 2010-01-03 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2010-03-01 | $0.00 derived: sum of 2 quarters · filed 2010-03-01 | $0.00 derived: sum of 3 quarters · filed 2010-03-01 | $0.00 10-K · filed 2010-03-01 | |
| 2009-09-27 | $0.00 10-Q · filed 2009-11-04 | $0.00 derived: sum of 2 quarters · filed 2009-11-04 | $0.00 10-Q · filed 2009-11-04 | $141.00M derived: sum of 4 quarters · filed 2011-02-25 | |
| 2009-06-28 | $0.00 10-Q · filed 2009-08-04 | $0.00 10-Q · filed 2009-08-04 | $141.00M derived: sum of 3 quarters · filed 2011-02-25 | $141.00M derived: sum of 4 quarters · filed 2011-02-25 | |
| 2009-03-29 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2010-03-01 | $141.00M derived: sum of 2 quarters · filed 2011-02-25 | $141.00M derived: sum of 3 quarters · filed 2011-02-25 | $181.00M derived: sum of 4 quarters · filed 2011-02-25 | |
| 2008-12-28 | $141.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $141.00M derived: sum of 2 quarters · filed 2011-02-25 | $181.00M derived: sum of 3 quarters · filed 2011-02-25 | $181.00M 10-K · filed 2011-02-25 | |
| 2008-09-28 | $0.00 10-Q · filed 2009-11-04 | $40.00M derived: sum of 2 quarters · filed 2009-11-04 | $40.00M 10-Q · filed 2009-11-04 | ||
| 2008-06-29 | $40.00M 10-Q · filed 2009-08-04 | $40.00M 10-Q · filed 2009-08-04 | |||
| 2007-12-30 | $807.00M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |